Immunoradiotherapy May Be a Promising Option in Cisplatin-Ineligible Head and Neck Cancer
Preclinical data has suggested that radiotherapy can increase sensitivity to immunotherapy and that immunotherapy can sensitize cancer cells to radiation.
Head and Neck Cancer
Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
New Dosing Schedule Approved for All Keytruda Indications
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Promising Clinical Activity for RT Plus ICIs in Locally Advanced Head and Neck Cancers
The majority of patients enrolled in this study were unable to receive cisplatin due to an ear-related comorbidity.
-
Loading...
-
Loading...
Next post in Head and Neck Cancer
